T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-09-09 12:48 (588 d 03:56 ago) – Posting: # 23282
Views: 2,392

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,987 posts in 4,824 threads, 1,665 registered users;
96 visitors (0 registered, 96 guests [including 7 identified bots]).
Forum time: 16:45 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5